Type 1 Diabetes Prevention: Screening Efforts and Prevention Studies in At-Risk Relatives and the General Population
Main Article Content
Abstract
Type 1 diabetes autoantibodies are detectable before the onset of clinical disease. Once an individual has ≥2 diabetes autoantibodies, their lifetime risk of developing clinical disease approaches 100%. While relatives of individuals with type 1 diabetes have a 15-fold increase in disease risk, 85-95% of type 1 diabetes diagnoses occur in people without affected relatives. Identification of multiple diabetes autoantibodies and subsequent education and monitoring prior to clinical type 1 diabetes diagnosis decreases the incidence of diabetic ketoacidosis at onset as well as other diabetes sequelae. Also, early risk recognition facilitates participation in clinical trials aimed at delay and prevention of clinical disease and/or treatment with teplizumab, an approved medication to delay onset of clinical type 1 diabetes in people with multiple diabetes autoantibodies and dysglycemia. Therefore, risk screening, which is currently recommended only for relatives of individuals with type 1 diabetes, should be expanded to include the general population.
Article Details
How to Cite
FARKAS, Hal Steven; LESCHEK, Ellen Werber.
Type 1 Diabetes Prevention: Screening Efforts and Prevention Studies in At-Risk Relatives and the General Population.
Medical Research Archives, [S.l.], v. 13, n. 10, oct. 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6880>. Date accessed: 14 nov. 2025.
doi: https://doi.org/10.18103/mra.v13i10.6880.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. The Environmental Determinants of Diabetes in the Young: University of South Florida. 2004. Accessed August 8, 2025. https://teddy.epi.usf.edu/index.htm
2. Kara Sweet. Who is at risk for type 1 diabetes? Breakthrough T1D. July 15, 2025. Accessed August 8, 2025. https://www.breakthrought1d.org/news-and-updates/who-is-at-risk-for-type-1-diabetes/
3. Karges B, Prinz N, Placzek K, et al. A Comparison of Familial and Sporadic Type 1 Diabetes Among Young Patients. Diabetes Care. 2021;44(5):1116-24. [PubMed: 33824143]
4. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-74. [PubMed: 6404926]
5. Sims EK, Besser REJ, Dayan C, et al. Screening for type 1 diabetes in the general population: a status report and perspective. Diabetes. 2022;71(4):610-23. [PubMed: 35316839]
6. Praveen PA, Hockett CW, Ong TC, et al. Diabetic ketoacidosis at diagnosis among youth with type 1 and type 2 diabetes: results from SEARCH (United States) and YDR (India) registries. Pediatr Diabetes. 2021;22(1):40-6. [PubMed: 31943641]
7. Simmons KM, Sims EK. Screening and prevention of type 1 diabetes: where are we? J Clin Endocrinol Metab. 2023;108(12):3067-79. [PubMed: 37290044]
8. Evans-Molina C, Oram RA. Teplizumab approval for type 1 diabetes in the USA. Lancet Diabetes Endocrinol. 2023;11(2):76-7. [PubMed: 36623518]
9. Gillespie KM, Gale EA, Bingley PJ. High familial risk and genetic susceptibility in early onset childhood diabetes. Diabetes. 2002;51(1):210-4. [PubMed: 11756343]
10. Bingley PJ, Wherrett DK, Shultz A, Rafkin LE, Atkinson MA, Greenbaum CJ. Type 1 Diabetes TrialNet: A multifaceted approach to bringing disease-modifying therapy to clinical use in type 1 diabetes. Diabetes Care. 2018;41(4):653-661. [PubMed: 29559451]
11. Type 1 Diabetes TrialNet. TrialNet Pathway to Prevention of Type 1 Diabetes. ClinicalTrials.gov: NCT00097292. Updated July 1, 2025. Accessed August 10, 2025. https://clinicaltrials.gov/study/NCT00097292
12. Marcovecchio ML, Hendriks AEJ, Delfin C, et al. INNODIA consortium. The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults. Diabetologia. 2024;67(6):995-1008. [PubMed: 38517484]
13. University of Cambridge. An Innovative Approach Towards Understanding and Arresting Type 1 Diabetes (INNODIA). ClinicalTrials.gov: NCT03936 634. Updated December 21, 2020. Accessed August 11, 2025. https://clinicaltrials.gov/study/NCT03936634?cond=INNODIA&rank=1
14. Wentworth JM, Sing ABE, Naselli G, et al. Islet autoantibody screening throughout Australia using in-home blood spot sampling: 2-year outcomes of Type1Screen. Diabetes Care. 2025;48(4):556-63. [PubMed: 39879258]
15. Winkler C, Haupt F, Heigermoser M, et al. Identification of infants with increased type 1 diabetes genetic risk for enrollment into primary prevention trials-GPPAD-02 study design and first results. Pediatr Diabetes. 2019;20(6):720-7. [PubMed: 31192505]
16. Ziegler AG, Achenbach P, Berner R, et al. Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. BMJ Open. 2019;9(6):e028578. [PubMed: 31256036]
17. Kuusela S, Keskinen P, Pokka T, Knip M, Ilonen J, Vähäsalo P, Veijola R. Extended family history of type 1 diabetes in HLA-predisposed children with and without islet autoantibodies. Pediatr Diabetes. 2020;21(8):1447-1456. [PubMed: 32939969]
18. Helsinki University. Research focusing on the occurrence of type 1 diabetes and celiac disease in newborns. Research Group: BABYSCREEN. https://www.helsinki.fi/fi/tutkimusryhmat/babyscreen. Published August 26, 2022. Accessed August 10, 2025.
19. Pacific Northwest Research Institute. Combined Antibody Screening for Celiac and Diabetes Evaluation (CASCADE) (ClinicalTrials.gov Identifier: NCT04677699). Retrieved August 12, 2025, from ClinicalTrials.gov
20. Sanford Research. Pediatric screening for type 1 diabetes and celiac disease integrated into routine care. PLEDGE pediatric screening study. https://research.sanfordhealth.org/fields-of-research/diabetes/pledge. Accessed August 10, 2025.
21. KXLG 99.1 Sanford PLEDGE study reaches milestone in type 1 diabetes and celiac disease research. https://www.mykxlg.com/news/state/sanford-pledge-study-reaches-milestone-in-type-1-diabetes-and-celiac-disease-research/article_6ed8843a-8a51-11ef-8a99-5bd850be8332.html Published October 14, 2024. Accessed August 10, 2025.
22. Ziegler AG, Kick K, Bonifacio E, et al; Fr1da Study Group. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA. 2020;323(4):339-51. [PubMed: 31990315]
23. Hummel S, Carl J, Friedl N, et al. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia. 2023;66(9):1633-42. [PubMed: 37329450]
24. Guertin KA, Repaske DR, Taylor JF, et al. Implementation of type 1 diabetes genetic risk screening in children in diverse communities: the Virginia PrIMeD project. Genome Med. 2024;16(1):31. [PubMed: 38355597]
25. McQueen RB, Geno Rasmussen C, Waugh K, et al. Cost and cost-effectiveness of large-scale screening for type 1 diabetes in Colorado. Diabetes Care. 2020;43(7):1496-1503. [PubMed: 32327420]
26. Stene LC, Ulriksen J, Magnus P, Joner G. Use of cod liver oil during pregnancy is associated with lower risk of type I diabetes in the offspring. Diabetologia. 2000;43(9):1093-8. [PubMed: 11043854]
27. Stene LC, Joner G; Norwegian Childhood Diabetes Study Group. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr. 2003;78(6):1128-34. [PubMed: 14668274]
28. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia. 1994;37(6):552-8. [PubMed: 7926338]
29. Zella JB, McCary LC, DeLuca HF. Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. Arch Biochem Biophys. 2003;417(1):77-80. [PubMed: 12921782]
30. Giulietti A, Gysemans C, Stoffels K, et al. Vitamin D deficiency in early life accelerates type 1 diabetes in non-obese diabetic mice. Diabetologia. 2004;47(3):451-62. [PubMed: 14758446]
31. Wicklow BA, Taback SP. Feasibility of a type 1 diabetes primary prevention trial using 2000 IU vitamin D3 in infants from the general population with increased HLA-associated risk. Ann N Y Acad Sci. 2006;1079:310-2. [PubMed: 17130571]
32. Chase HP, Boulware D, Rodriguez H, et al. Effect of docosahexaenoic acid supplementation on inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes. Pediatr Diabetes. 2015;16(4):271-9. [PubMed: 25039804]
33. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10252-6. [PubMeD: 1946445]
34. Bonifacio E, Ziegler AG, Klingensmith G, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA. 2015;313(15):1541-9. [PubMed: 25898052]
35. Ziegler AG, Achenbach P, Berner R, et al. Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. BMJ Open. 2019;9(6):e028578. [PubMeD: 31256036]
36. Assfalg R, Knoop J, Hoffman KL, et al. Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial. Diabetologia. 2021;64(5):1079-92. [PubMed: 33515070]
37. Achenbach, P. PINIT Study – An immune efficacy study for primary prevention using intranasal insulin therapy in islet autoantibody negative children at high risk for type 1 diabetes. EU Clinical Trials Register: EudraCT No. 2015-003379-31. Updated April 2, 2022. Accessed August 2, 2025. EudraCT Number 2015-003379-31 - Clinical trial results - EU Clinical Trials Register
38. Knip M, Virtanen SM, Seppä K, et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med. 2010;363(20):1900-8. [PubMed: 21067382]
39. Vaarala O, Ilonen J, Ruohtula T, et al. Removal of bovine insulin from cow's milk formula and early initiation of beta-cell autoimmunity in the FINDIA Pilot Study. Arch Pediatr Adolesc Med. 2012;166(7):608-14. [PubMed: 22393174]
40. Knip M, Åkerblom HK, Al Taji E, et al. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes: the TRIGR Randomized Clinical Trial. JAMA. 2018;319(1):38-48. [PubMed: 29297078]
41. Ziegler AG, Schmid S, Huber D, Hummel M, Bonifacio E. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA. 2003;290(13):1721-8. [PubMeD: 14519706]
42. Norris JM, Barriga K, Klingensmith G, Hoffman M, Eisenbarth GS, Erlich HA, Rewers M. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA. 2003;290(13):1713-20. [PubMed: 14519705]
43. Pastore MR, Bazzigaluppi E, Belloni C, Arcovio C, Bonifacio E, Bosi E. Six months of gluten-free diet do not influence autoantibody titers, but improve insulin secretion in subjects at high risk for type 1 diabetes. J Clin Endocrinol Metab. 2003;88(1):162-5. [PubMed: 12519846]
44. Hummel S, Pflüger M, Hummel M, Bonifacio E, Ziegler AG. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care. 2011;34(6):1301-5. [PubMeD: 21515839]
45. Uusitalo U, Liu X, Yang J, et al. Association of early exposure of probiotics and islet autoimmunity in the TEDDY study. JAMA Pediatr. 2016;170(1):20-8. [PubMed: 26552054]
46. Ziegler AG, Arnolds S, Kölln A, et al. Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol. BMJ Open. 2021;11(11):e052449. [PubMed: 34753762]
47. Yamada K, Nonaka K, Hanafusa T, Miyazaki A, Toyoshima H, Tarui S. Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. An observation in nonobese diabetic (NOD) mice. Diabetes. 1982;31(9):749-53. [PubMed: 6219022]
48. Elliott RB, Pilcher CC, Stewart A, Fergusson D, McGregor MA. The use of nicotinamide in the prevention of type 1 diabetes. Ann N Y Acad Sci. 1993;696:333-41. [PubMed: 8109840]
49. Lampeter EF, Klinghammer A, Scherbaum WA, et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. Diabetes. 1998;47(6):980-4. [PubMed: 9604880]
50. Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004;363(9413):925-31. [PubMed: 15043959]
51. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet. 1993;341(8850):927-8. [PubMed: 8096268]
52. Ziegler AG, Bachmann W, Rabl W. Prophylactic insulin treatment in relatives at high risk for type 1 diabetes. Diabetes Metab Rev. 1993;9(4):289-93. [PubMeD: 7924826]
53. Füchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia. 1998;41(5):536-41. [PubMeD: 9628270]
54. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005;28(5):1068-76. [PubMed: 15855569]
55. Carel J-C, Landais P, Bougnères P. Therapy to prevent type 1 diabetes mellitus. N Engl J Med. 2002;347(14):1115-6. [PubMed: 12362017]
56. Vandemeulebroucke E, Gorus FK, Decochez K, et al. Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes Metab. 2009;35(4):319-27. [PubMed: 19647467]
57. Zhong ZJ, Davidson L, Eisenbarth GS, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA. 1991;88:10252–6. [PubMed: 1946445]
58. Zhong ZJ, Shoelson S, Miller A, Weiner HL. Insulitis is suppressed in NOD mice by oral administration of insulin peptides and glucagon. FASEB J. 1992;6: 1693.
59. Muir A, Schatz D, Maclaren N. Antigen-specific immunotherapy: oral tolerance and subcutaneous immunization in the treatment of insulin-dependent diabetes. Diabetes Metab Rev. 1993;9(4):279-87. [PubMed: 7924825]
60. Bergerot I, Fabien N, Maguer V, Thivolet C. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J Autoimmun. 1994;7(5):655-63. [PubMed: 7840857]
61. Polanski M, Melican NS, Zhang J, Weiner HL. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J Autoimmun. 1997;10(4):339-46. [PubMed: 9237797]
62. Ploix C, Bergerot I, Fabien N, Perche S, Moulin V, Thivolet C. Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes. Diabetes. 1998;47(1):39-44. [PubMed: 9421372]
63. Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA. 2017;318(19):1891-1902. [PubMed: 29164254]
64. Forschergruppe Diabetes Group, Fr1da Insulin Intervention. ClinicalTrials.gov: NCT02620072. Updated October 8, 2024. Accessed August 10, 2025. https://clinicaltrials.gov/study/NCT02620072?cond=Fr1da&rank=1
65. Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol. 1993;5(9):1159-65. [PubMed: 7694644]
66. Harrison LC, Honeyman MC, Steele CE, \ et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care. 2004;27(10):2348-55. [PubMed: 15451899]
67. Näntö-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet. 2008;372(9651):1746-55. [PubMeD: 18814906]
68. Melbourne Health. Trial of intranasal insulin in children and young adults at risk of type 1 diabetes (INITII). ClinicalTrials.gov: NCT00336674. Updated October 8, 2020. Accessed August 11, 2025. https://clinicaltrials.gov/study/NCT00336674?cond=NCT00336674&rank=1
69. Jacobsen LM, Schatz DA, Herold KC, et al. Prevention of Type 1 Diabetes. 2024 Jun 6. In: Lawrence JM, Casagrande SS, Herman WH, et al., editors. Diabetes in America [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK604182/
70. Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M. The challenge of modulating β-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2019;7(1):52-64. [PubMed: 30528099]
71. Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62(11):3766-74. [PubMed: 23835333]
72. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1692-8. [PubMed: 12037148]
73. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352(25):2598-608. [PubMed: 15972866]
74. Hagopian W, Ferry RJ Jr, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013;62(11):3901-8. [PubMed: 23801579]
75. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011;378(9790):487-97. [PubMed: 21719095]
76. Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603-613. [PubMed: 31180194]
77. Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13(583):eabc8980. [PubMed: 33658358]
78. Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021;17(3):150-161. [PubMed: 33293704]
79. Mallone R, Eizirik DL. Presumption of innocence for beta cells: why are they vulnerable autoimmune targets in type 1 diabetes? Diabetologia. 2020;63(10):1999-2006. [PubMed: 32894310]
80. Cunha DA, Ladrière L, Ortis F, et al. Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes. 2009;58(12):2851-62. [PubMed: 19720788]
81. Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ. Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology. 2008;149(3):1338-49. [PubMed: 18063685]
82. von Herrath M, Bain SC, Bode B, et al. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021;9(4):212-224. [PubMed: 33662334]
83. Kero J, Koskenniemi JJ, Karsikas S, Pokka T, Lou O, Toppari J, Veijola R. INnoVative trial design for testing the efficacy, safety and tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA). Diabet Med. 2022;39(10):e14913. [PubMed: 35797241]
84. Emami J, Gerstein HC, Pasutto FM, Jamali F. Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. Can J Physiol Pharmacol. 1999;77(2):118-23. [PubMed: 10535702]
85. Solomon DH, Garg R, Lu B, et al. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res. 2014;66(8):1246-51. [PubMed: 24470436]
86. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525-31. [PubMed: 21693740]
87. Penn SK, Kao AH, Schott LL, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2010;37(6):1136-42. [PubMed: 20436082]
88. Chen YM, Lin CH, Lan TH, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology. 2015;54(7):1244-9. [PubMed: 25587177]
89. Wasko MC, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FG. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia. 2015;58(10):2336-43. [PubMed: 26197707]
90. Libman I, Bingley PJ, Becker D, et al. Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care. 2023;46(11): 2035–43. [PubMed: 37708415]
91. Orban T, Bundy B, Becker DJ, et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care. 2014;37(4):1069-75. [PubMed: 24296850]
92. Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):412-9. [PubMed: 21719096]
93. Russell WE, Bundy BN, Anderson MS, et al. Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial. Diabetes Care. 2023;46(5):1005-13. [PubMed: 36920087]
94. Yamamoto K, Okamoto A, Fujio K. Antigen-specific immunotherapy for autoimmune diseases. Expert Opin Biol Ther. 2007;7(3):359-67. [PubMed: 17309327]
95. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008;359(18):1909-20. [PubMed: 18843118]
96. Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011; 378(9788):319-27. [Pubmed: 21714999]
97. Ludvigsson J, Wahlberg J, Casas R. Intralymphatic injection of autoantigen in type 1 diabetes. N Engl J Med. 2017;376(7):697-9. [PubMed: 28199812] Erratum in: N Engl J Med. 2017;377(4):405. [PubMed: 28199812]
98. Ludvigsson J, Sumnik Z, Pelikanova T, et al. Intralymphatic glutamic acid decarboxylase with vitamin D supplementation in recent-onset type 1 diabetes: a double-blind, randomized, placebo-controlled phase IIb trial. Diabetes Care. 2021;44(7):1604-12. [PubMed: 34021020]
99. Nowak C, Lind M, Sumnik Z, et al. Intralymphatic GAD-Alum (Diamyd®) improves glycemic control in type 1 diabetes with HLA DR3-DQ2. J Clin Endocrinol Metab. 2022;107(9):2644-51. [PubMed: 35665810]
100. Elding Larsson H, Lundgren M, Jonsdottir B, Cuthbertson D, Krischer J; DiAPREV-IT Study Group. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial. Pediatr Diabetes. 2018;19(3):410-9. [PubMed: 29171140]
101. Diamyd Medical AB. Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals At Risk for Type 1 Diabetes. ClinicalTrials.gov: NCT05683990. Updated November 20, 2024. Accessed August 10, 2025. https://clinicaltrials.gov/study/NCT05683990?cond=diaprecise&rank=1
102. The Children’s Hospital at Westmead. CoRD Study. Australia New Zealand Clinical Trial Registry: 12613000186752. Accessed August 10, 2025. http://www.cordtrial.org
103. Lernmark Å, Agardh D, Akolkar B, et al. Looking back at the TEDDY study: lessons and future directions. Nat Rev Endocrinol. 2025;21(3):154-65. [PubMed: 39496810]
104. Rewers M, Hyöty H, Lernmark Å, et al. TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) Study: 2018 Update. Curr Diab Rep. 2018;18(12):136. [PubMed: 30353256]
2. Kara Sweet. Who is at risk for type 1 diabetes? Breakthrough T1D. July 15, 2025. Accessed August 8, 2025. https://www.breakthrought1d.org/news-and-updates/who-is-at-risk-for-type-1-diabetes/
3. Karges B, Prinz N, Placzek K, et al. A Comparison of Familial and Sporadic Type 1 Diabetes Among Young Patients. Diabetes Care. 2021;44(5):1116-24. [PubMed: 33824143]
4. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-74. [PubMed: 6404926]
5. Sims EK, Besser REJ, Dayan C, et al. Screening for type 1 diabetes in the general population: a status report and perspective. Diabetes. 2022;71(4):610-23. [PubMed: 35316839]
6. Praveen PA, Hockett CW, Ong TC, et al. Diabetic ketoacidosis at diagnosis among youth with type 1 and type 2 diabetes: results from SEARCH (United States) and YDR (India) registries. Pediatr Diabetes. 2021;22(1):40-6. [PubMed: 31943641]
7. Simmons KM, Sims EK. Screening and prevention of type 1 diabetes: where are we? J Clin Endocrinol Metab. 2023;108(12):3067-79. [PubMed: 37290044]
8. Evans-Molina C, Oram RA. Teplizumab approval for type 1 diabetes in the USA. Lancet Diabetes Endocrinol. 2023;11(2):76-7. [PubMed: 36623518]
9. Gillespie KM, Gale EA, Bingley PJ. High familial risk and genetic susceptibility in early onset childhood diabetes. Diabetes. 2002;51(1):210-4. [PubMed: 11756343]
10. Bingley PJ, Wherrett DK, Shultz A, Rafkin LE, Atkinson MA, Greenbaum CJ. Type 1 Diabetes TrialNet: A multifaceted approach to bringing disease-modifying therapy to clinical use in type 1 diabetes. Diabetes Care. 2018;41(4):653-661. [PubMed: 29559451]
11. Type 1 Diabetes TrialNet. TrialNet Pathway to Prevention of Type 1 Diabetes. ClinicalTrials.gov: NCT00097292. Updated July 1, 2025. Accessed August 10, 2025. https://clinicaltrials.gov/study/NCT00097292
12. Marcovecchio ML, Hendriks AEJ, Delfin C, et al. INNODIA consortium. The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults. Diabetologia. 2024;67(6):995-1008. [PubMed: 38517484]
13. University of Cambridge. An Innovative Approach Towards Understanding and Arresting Type 1 Diabetes (INNODIA). ClinicalTrials.gov: NCT03936 634. Updated December 21, 2020. Accessed August 11, 2025. https://clinicaltrials.gov/study/NCT03936634?cond=INNODIA&rank=1
14. Wentworth JM, Sing ABE, Naselli G, et al. Islet autoantibody screening throughout Australia using in-home blood spot sampling: 2-year outcomes of Type1Screen. Diabetes Care. 2025;48(4):556-63. [PubMed: 39879258]
15. Winkler C, Haupt F, Heigermoser M, et al. Identification of infants with increased type 1 diabetes genetic risk for enrollment into primary prevention trials-GPPAD-02 study design and first results. Pediatr Diabetes. 2019;20(6):720-7. [PubMed: 31192505]
16. Ziegler AG, Achenbach P, Berner R, et al. Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. BMJ Open. 2019;9(6):e028578. [PubMed: 31256036]
17. Kuusela S, Keskinen P, Pokka T, Knip M, Ilonen J, Vähäsalo P, Veijola R. Extended family history of type 1 diabetes in HLA-predisposed children with and without islet autoantibodies. Pediatr Diabetes. 2020;21(8):1447-1456. [PubMed: 32939969]
18. Helsinki University. Research focusing on the occurrence of type 1 diabetes and celiac disease in newborns. Research Group: BABYSCREEN. https://www.helsinki.fi/fi/tutkimusryhmat/babyscreen. Published August 26, 2022. Accessed August 10, 2025.
19. Pacific Northwest Research Institute. Combined Antibody Screening for Celiac and Diabetes Evaluation (CASCADE) (ClinicalTrials.gov Identifier: NCT04677699). Retrieved August 12, 2025, from ClinicalTrials.gov
20. Sanford Research. Pediatric screening for type 1 diabetes and celiac disease integrated into routine care. PLEDGE pediatric screening study. https://research.sanfordhealth.org/fields-of-research/diabetes/pledge. Accessed August 10, 2025.
21. KXLG 99.1 Sanford PLEDGE study reaches milestone in type 1 diabetes and celiac disease research. https://www.mykxlg.com/news/state/sanford-pledge-study-reaches-milestone-in-type-1-diabetes-and-celiac-disease-research/article_6ed8843a-8a51-11ef-8a99-5bd850be8332.html Published October 14, 2024. Accessed August 10, 2025.
22. Ziegler AG, Kick K, Bonifacio E, et al; Fr1da Study Group. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA. 2020;323(4):339-51. [PubMed: 31990315]
23. Hummel S, Carl J, Friedl N, et al. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia. 2023;66(9):1633-42. [PubMed: 37329450]
24. Guertin KA, Repaske DR, Taylor JF, et al. Implementation of type 1 diabetes genetic risk screening in children in diverse communities: the Virginia PrIMeD project. Genome Med. 2024;16(1):31. [PubMed: 38355597]
25. McQueen RB, Geno Rasmussen C, Waugh K, et al. Cost and cost-effectiveness of large-scale screening for type 1 diabetes in Colorado. Diabetes Care. 2020;43(7):1496-1503. [PubMed: 32327420]
26. Stene LC, Ulriksen J, Magnus P, Joner G. Use of cod liver oil during pregnancy is associated with lower risk of type I diabetes in the offspring. Diabetologia. 2000;43(9):1093-8. [PubMed: 11043854]
27. Stene LC, Joner G; Norwegian Childhood Diabetes Study Group. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr. 2003;78(6):1128-34. [PubMed: 14668274]
28. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia. 1994;37(6):552-8. [PubMed: 7926338]
29. Zella JB, McCary LC, DeLuca HF. Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. Arch Biochem Biophys. 2003;417(1):77-80. [PubMed: 12921782]
30. Giulietti A, Gysemans C, Stoffels K, et al. Vitamin D deficiency in early life accelerates type 1 diabetes in non-obese diabetic mice. Diabetologia. 2004;47(3):451-62. [PubMed: 14758446]
31. Wicklow BA, Taback SP. Feasibility of a type 1 diabetes primary prevention trial using 2000 IU vitamin D3 in infants from the general population with increased HLA-associated risk. Ann N Y Acad Sci. 2006;1079:310-2. [PubMed: 17130571]
32. Chase HP, Boulware D, Rodriguez H, et al. Effect of docosahexaenoic acid supplementation on inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes. Pediatr Diabetes. 2015;16(4):271-9. [PubMed: 25039804]
33. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10252-6. [PubMeD: 1946445]
34. Bonifacio E, Ziegler AG, Klingensmith G, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA. 2015;313(15):1541-9. [PubMed: 25898052]
35. Ziegler AG, Achenbach P, Berner R, et al. Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. BMJ Open. 2019;9(6):e028578. [PubMeD: 31256036]
36. Assfalg R, Knoop J, Hoffman KL, et al. Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial. Diabetologia. 2021;64(5):1079-92. [PubMed: 33515070]
37. Achenbach, P. PINIT Study – An immune efficacy study for primary prevention using intranasal insulin therapy in islet autoantibody negative children at high risk for type 1 diabetes. EU Clinical Trials Register: EudraCT No. 2015-003379-31. Updated April 2, 2022. Accessed August 2, 2025. EudraCT Number 2015-003379-31 - Clinical trial results - EU Clinical Trials Register
38. Knip M, Virtanen SM, Seppä K, et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med. 2010;363(20):1900-8. [PubMed: 21067382]
39. Vaarala O, Ilonen J, Ruohtula T, et al. Removal of bovine insulin from cow's milk formula and early initiation of beta-cell autoimmunity in the FINDIA Pilot Study. Arch Pediatr Adolesc Med. 2012;166(7):608-14. [PubMed: 22393174]
40. Knip M, Åkerblom HK, Al Taji E, et al. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes: the TRIGR Randomized Clinical Trial. JAMA. 2018;319(1):38-48. [PubMed: 29297078]
41. Ziegler AG, Schmid S, Huber D, Hummel M, Bonifacio E. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA. 2003;290(13):1721-8. [PubMeD: 14519706]
42. Norris JM, Barriga K, Klingensmith G, Hoffman M, Eisenbarth GS, Erlich HA, Rewers M. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA. 2003;290(13):1713-20. [PubMed: 14519705]
43. Pastore MR, Bazzigaluppi E, Belloni C, Arcovio C, Bonifacio E, Bosi E. Six months of gluten-free diet do not influence autoantibody titers, but improve insulin secretion in subjects at high risk for type 1 diabetes. J Clin Endocrinol Metab. 2003;88(1):162-5. [PubMed: 12519846]
44. Hummel S, Pflüger M, Hummel M, Bonifacio E, Ziegler AG. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care. 2011;34(6):1301-5. [PubMeD: 21515839]
45. Uusitalo U, Liu X, Yang J, et al. Association of early exposure of probiotics and islet autoimmunity in the TEDDY study. JAMA Pediatr. 2016;170(1):20-8. [PubMed: 26552054]
46. Ziegler AG, Arnolds S, Kölln A, et al. Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol. BMJ Open. 2021;11(11):e052449. [PubMed: 34753762]
47. Yamada K, Nonaka K, Hanafusa T, Miyazaki A, Toyoshima H, Tarui S. Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. An observation in nonobese diabetic (NOD) mice. Diabetes. 1982;31(9):749-53. [PubMed: 6219022]
48. Elliott RB, Pilcher CC, Stewart A, Fergusson D, McGregor MA. The use of nicotinamide in the prevention of type 1 diabetes. Ann N Y Acad Sci. 1993;696:333-41. [PubMed: 8109840]
49. Lampeter EF, Klinghammer A, Scherbaum WA, et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. Diabetes. 1998;47(6):980-4. [PubMed: 9604880]
50. Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004;363(9413):925-31. [PubMed: 15043959]
51. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet. 1993;341(8850):927-8. [PubMed: 8096268]
52. Ziegler AG, Bachmann W, Rabl W. Prophylactic insulin treatment in relatives at high risk for type 1 diabetes. Diabetes Metab Rev. 1993;9(4):289-93. [PubMeD: 7924826]
53. Füchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia. 1998;41(5):536-41. [PubMeD: 9628270]
54. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005;28(5):1068-76. [PubMed: 15855569]
55. Carel J-C, Landais P, Bougnères P. Therapy to prevent type 1 diabetes mellitus. N Engl J Med. 2002;347(14):1115-6. [PubMed: 12362017]
56. Vandemeulebroucke E, Gorus FK, Decochez K, et al. Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes Metab. 2009;35(4):319-27. [PubMed: 19647467]
57. Zhong ZJ, Davidson L, Eisenbarth GS, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA. 1991;88:10252–6. [PubMed: 1946445]
58. Zhong ZJ, Shoelson S, Miller A, Weiner HL. Insulitis is suppressed in NOD mice by oral administration of insulin peptides and glucagon. FASEB J. 1992;6: 1693.
59. Muir A, Schatz D, Maclaren N. Antigen-specific immunotherapy: oral tolerance and subcutaneous immunization in the treatment of insulin-dependent diabetes. Diabetes Metab Rev. 1993;9(4):279-87. [PubMed: 7924825]
60. Bergerot I, Fabien N, Maguer V, Thivolet C. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J Autoimmun. 1994;7(5):655-63. [PubMed: 7840857]
61. Polanski M, Melican NS, Zhang J, Weiner HL. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J Autoimmun. 1997;10(4):339-46. [PubMed: 9237797]
62. Ploix C, Bergerot I, Fabien N, Perche S, Moulin V, Thivolet C. Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes. Diabetes. 1998;47(1):39-44. [PubMed: 9421372]
63. Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA. 2017;318(19):1891-1902. [PubMed: 29164254]
64. Forschergruppe Diabetes Group, Fr1da Insulin Intervention. ClinicalTrials.gov: NCT02620072. Updated October 8, 2024. Accessed August 10, 2025. https://clinicaltrials.gov/study/NCT02620072?cond=Fr1da&rank=1
65. Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol. 1993;5(9):1159-65. [PubMed: 7694644]
66. Harrison LC, Honeyman MC, Steele CE, \ et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care. 2004;27(10):2348-55. [PubMed: 15451899]
67. Näntö-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet. 2008;372(9651):1746-55. [PubMeD: 18814906]
68. Melbourne Health. Trial of intranasal insulin in children and young adults at risk of type 1 diabetes (INITII). ClinicalTrials.gov: NCT00336674. Updated October 8, 2020. Accessed August 11, 2025. https://clinicaltrials.gov/study/NCT00336674?cond=NCT00336674&rank=1
69. Jacobsen LM, Schatz DA, Herold KC, et al. Prevention of Type 1 Diabetes. 2024 Jun 6. In: Lawrence JM, Casagrande SS, Herman WH, et al., editors. Diabetes in America [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK604182/
70. Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M. The challenge of modulating β-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2019;7(1):52-64. [PubMed: 30528099]
71. Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62(11):3766-74. [PubMed: 23835333]
72. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1692-8. [PubMed: 12037148]
73. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352(25):2598-608. [PubMed: 15972866]
74. Hagopian W, Ferry RJ Jr, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013;62(11):3901-8. [PubMed: 23801579]
75. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011;378(9790):487-97. [PubMed: 21719095]
76. Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603-613. [PubMed: 31180194]
77. Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13(583):eabc8980. [PubMed: 33658358]
78. Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021;17(3):150-161. [PubMed: 33293704]
79. Mallone R, Eizirik DL. Presumption of innocence for beta cells: why are they vulnerable autoimmune targets in type 1 diabetes? Diabetologia. 2020;63(10):1999-2006. [PubMed: 32894310]
80. Cunha DA, Ladrière L, Ortis F, et al. Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes. 2009;58(12):2851-62. [PubMed: 19720788]
81. Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ. Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology. 2008;149(3):1338-49. [PubMed: 18063685]
82. von Herrath M, Bain SC, Bode B, et al. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021;9(4):212-224. [PubMed: 33662334]
83. Kero J, Koskenniemi JJ, Karsikas S, Pokka T, Lou O, Toppari J, Veijola R. INnoVative trial design for testing the efficacy, safety and tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA). Diabet Med. 2022;39(10):e14913. [PubMed: 35797241]
84. Emami J, Gerstein HC, Pasutto FM, Jamali F. Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. Can J Physiol Pharmacol. 1999;77(2):118-23. [PubMed: 10535702]
85. Solomon DH, Garg R, Lu B, et al. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res. 2014;66(8):1246-51. [PubMed: 24470436]
86. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525-31. [PubMed: 21693740]
87. Penn SK, Kao AH, Schott LL, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2010;37(6):1136-42. [PubMed: 20436082]
88. Chen YM, Lin CH, Lan TH, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology. 2015;54(7):1244-9. [PubMed: 25587177]
89. Wasko MC, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FG. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia. 2015;58(10):2336-43. [PubMed: 26197707]
90. Libman I, Bingley PJ, Becker D, et al. Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care. 2023;46(11): 2035–43. [PubMed: 37708415]
91. Orban T, Bundy B, Becker DJ, et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care. 2014;37(4):1069-75. [PubMed: 24296850]
92. Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):412-9. [PubMed: 21719096]
93. Russell WE, Bundy BN, Anderson MS, et al. Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial. Diabetes Care. 2023;46(5):1005-13. [PubMed: 36920087]
94. Yamamoto K, Okamoto A, Fujio K. Antigen-specific immunotherapy for autoimmune diseases. Expert Opin Biol Ther. 2007;7(3):359-67. [PubMed: 17309327]
95. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008;359(18):1909-20. [PubMed: 18843118]
96. Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011; 378(9788):319-27. [Pubmed: 21714999]
97. Ludvigsson J, Wahlberg J, Casas R. Intralymphatic injection of autoantigen in type 1 diabetes. N Engl J Med. 2017;376(7):697-9. [PubMed: 28199812] Erratum in: N Engl J Med. 2017;377(4):405. [PubMed: 28199812]
98. Ludvigsson J, Sumnik Z, Pelikanova T, et al. Intralymphatic glutamic acid decarboxylase with vitamin D supplementation in recent-onset type 1 diabetes: a double-blind, randomized, placebo-controlled phase IIb trial. Diabetes Care. 2021;44(7):1604-12. [PubMed: 34021020]
99. Nowak C, Lind M, Sumnik Z, et al. Intralymphatic GAD-Alum (Diamyd®) improves glycemic control in type 1 diabetes with HLA DR3-DQ2. J Clin Endocrinol Metab. 2022;107(9):2644-51. [PubMed: 35665810]
100. Elding Larsson H, Lundgren M, Jonsdottir B, Cuthbertson D, Krischer J; DiAPREV-IT Study Group. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial. Pediatr Diabetes. 2018;19(3):410-9. [PubMed: 29171140]
101. Diamyd Medical AB. Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals At Risk for Type 1 Diabetes. ClinicalTrials.gov: NCT05683990. Updated November 20, 2024. Accessed August 10, 2025. https://clinicaltrials.gov/study/NCT05683990?cond=diaprecise&rank=1
102. The Children’s Hospital at Westmead. CoRD Study. Australia New Zealand Clinical Trial Registry: 12613000186752. Accessed August 10, 2025. http://www.cordtrial.org
103. Lernmark Å, Agardh D, Akolkar B, et al. Looking back at the TEDDY study: lessons and future directions. Nat Rev Endocrinol. 2025;21(3):154-65. [PubMed: 39496810]
104. Rewers M, Hyöty H, Lernmark Å, et al. TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) Study: 2018 Update. Curr Diab Rep. 2018;18(12):136. [PubMed: 30353256]